Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.02.19
Views: 1442

Dr Sumit Subudhi - MD Anderson Cancer Center, Houston, USA

Dr Sumit Subudhi speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about initial results from the CheckMate 650 study looking at nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer.

He reports that the combination of treatment can lead to some very promising results, with two patients in his own institution showing PSA levels of 0 and no sign of disease after 1.5 years.

Dr Subudhi acknowledges that not all patients have benefited and that biomarkers, such as the tumour mutational burden, need to be further evaluated to predict which patients will respond.

Read more about this work here.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation